Esperion Therapeutics (ESPR) Assets (2012 - 2026)

Esperion Therapeutics has reported Assets for 15 years, with the latest figure at $462.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 42.74% year-over-year to $462.5 million; the trailing twelve-month figure through Mar 2026 stood at $462.5 million (up 42.74% YoY), and the FY2025 full-year result was $465.9 million, up 35.5% from the prior year.
• Assets for Q1 2026 stood at $462.5 million, down from $465.9 million in the prior quarter.
• The five-year high for Assets was $465.9 million in Q4 2025, with the low at $205.8 million in Q4 2023.
• Historically, Assets has averaged $321.6 million across 5 years, with a median of $324.0 million in 2025.
• Annual changes were most pronounced in 2022 — Assets sank 35.02% — and 2024, when it soared 67.07%.
• Esperion Therapeutics' Assets stood at $247.9 million in 2022, then dropped by 17.0% to $205.8 million in 2023, then jumped by 67.07% to $343.8 million in 2024, then surged by 35.5% to $465.9 million in 2025, then dropped by 0.72% to $462.5 million in 2026.
• The last three Assets figures came in at $462.5 million (Q1 2026), $465.9 million (Q4 2025), and $364.0 million (Q3 2025), per Business Quant data.